Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

Menin inhibitors, including revumenib, bleximenib, and ziftomenib, show promise in treating AML, especially in NPM1-mutated and KMT2A-rearranged cases. Revumenib combined with azacitidine and ...

Hulk Hogan died of an acute myocardial infarction — commonly known as a heart attack — according to a report from Page Six. Documents obtained by the outlet reveal his cause of death, as well as a ...

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment—immunotherapy—may help change the environment where cancer cells live, ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with certain subtypes of acute myeloid leukemia (AML). The treatment works by using a ...

Decitabine/cedazuridine plus venetoclax met its primary endpoint with a complete response rate of 46.5%. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase ...

(RTTNews) - Kura Oncology Inc. (KURA) and Kyowa Kirin Co., Ltd. announced the U.S. Food and Drug Administration has accepted Kuras New Drug Application or NDA seeking full approval for ziftomenib as a ...

Outcomes for adults with KMT2A-r acute myeloid leukemia treated with venetoclax plus azacitidine (Ven/Aza) or intensive chemotherapy (IC): A single-center retrospective study.

Activating AML patients through empowering cancer communication strategies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.